Application note: CAR T Cell Research
Posted: 13 December 2019 | Bio-Techne | No comments yet
Chimeric antigen receptor (CAR) T cell transfer has had success as a treatment for leukemia and lymphoma, but solid tumors have been more challenging due to the rarity of true tumor-specific target molecules and the immunosuppressive nature of the tumor microenvironment.
New CAR strategies, continued improvements to T cell expansion methods, and combining adoptive cell transfer with other approaches such as immune checkpoint blockade, will be crucial moving forward. Trust our wide range of proteins, antibodies, kits, and assays to activate, expand, characterize, and functionally verify your CAR T cells.
Related content from this organisation
Related topics
Antibodies, Assays, Chimeric antigen receptors (CARs), Protein
Related organisations
Bio-Techne